BNT111
- Generic Name
- BNT111
- Drug Type
- Biotech
- Background
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
Phase 2
Active, not recruiting
- Conditions
- Unresectable MelanomaMelanoma Stage IIIMelanoma Stage IV
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 184
- Registration Number
- NCT04526899
- Locations
- 🇵🇱
Zachodniopomorskie Centrum Onkologii, Szczecin, Poland
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Spain
🇺🇸Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath